Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Alcohol Use Disorder
Interventions: Exenatide, Sham injection; Drug · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Disease
Interventions: AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: End Stage Renal Disease, Anemia
Interventions: Roxadustat, Epoetin Alfa, Placebo; Drug · Other
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more

Conditions: Aspergillosis
Interventions: Voriconazole, micafungin; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Little Rock, Arkansas

Conditions: PTSD, Alcohol Use Disorder
Interventions: Sertraline, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostatic Neoplasms
Interventions: Docetaxel, Prednisone, Intetumumab, Placebo; Drug · Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Birmingham, Alabama • Los Angeles, California • San Bernardino, California + 4 more

Conditions: Caffeine
Interventions: Caffeine; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Relapsing Multiple Sclerosis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more

Conditions: Diabetes Mellitus, Type 1, Hyperlipidemias
Interventions: Colesevelam HCl, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: PCOS
Interventions: OCP + Metformin, OCP + Placebo, Metformin + Placebo; Drug
Lead sponsor: Anuja Dokras; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Cocaine Dependence
Interventions: levodopa, Placebo, Cognitive Behavioral Therapy, Contingency Management; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Crohn Colitis
Interventions: Remestemcel-L, Placebo; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions: VT30; Drug
Lead sponsor: Venthera, Inc., a BridgeBio company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more

Conditions: Brain Concussion, Brain Trauma, Attention Concentration Difficulty, Brain Injuries, Brain Injuries, Traumatic, Neurocognitive Dysfunction, Attention Impaired, Memory Impairment, Mild Traumatic Brain Injury, Mild Cognitive Impairment
Interventions: active tDCS and cognitive training intervention, sham tDCS and cognitive training intervention; Combination Product
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Postoperative Cognitive Decline, Postoperative Delirium
Interventions: Daridorexant 50 mg, Placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Interventions: Droxidopa capsules, Placebo; Drug · Other
Lead sponsor: Giuseppe Cullaro, MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Menopause, Cognitive Disturbances
Interventions: atomoxetine, placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions: FODMAP-targeting digestive enzyme blend, Placebo; Dietary Supplement · Other
Lead sponsor: Kiwi Health Inc; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alzheimer Dementia
Interventions: Methylphenidate Extended Release Oral Capsule, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 95 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Bipolar Disorder
Interventions: Olanzapine, Paliperidone ER, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 16
States / cities: Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more

Conditions: FSHD - Facioscapulohumeral Muscular Dystrophy
Interventions: ULSC, Placebo; Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 15 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Heart Failure, Type 2 Diabetes Mellitus
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 94
States / cities: Alexander City, Alabama • Cottonwood, Arizona • Little Rock, Arkansas + 83 more

Conditions: Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
Interventions: Brentuximab Vedotin, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more

Search by objective public record fields.

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

Early Versus Routine Caffeine Administration in Extremely Preterm Neonates

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus

Comparing the Effects of Oral Contraceptive Pills Versus Metformin

Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

tDCS and Cognitive Training in Active Duty Service Members With Mild TBI: A Pilot Study

Daridorexant to Prevent Post-cardiotomy Delirium

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Brentuximab Vedotin for Systemic Sclerosis